The European Centre for Disease Prevention and Control (ECDC) released an interim analysis of their multi-country vaccine effectiveness study that is ongoing since 8 October 2021. This study investigates vaccine effectiveness against severe acute respiratory infection (SARI) due to SARS-CoV-2 in the hospital setting.
Ages 20-29 were covered in this report for the first time, making it a wider age range when compared to the previous report. The study period was shorter for this analysis and focused on vaccine effectiveness estimates from December 2021-July 2022, representing the Omicron dominant period. Most of the participants received the Pfizer/BioNTech vaccine. Across all age groups (20 years and older), the effectiveness of vaccination with only the primary series proved to be lower than for the primary series with a booster.
Read more about the ECDC interim analysis of COVID-19 vaccines from March here.